According to Valery Malashko, the Minister of Health of Belarus, India is a strategic partner for Belarus in the area of pharmaceuticals.
“We acquire more than 250 substances from Indian enterprises. The successes of Belarusian pharmaceutical industry are well-known but, at the same time, we must reach new levels, and introduce new medicinal products and technologies. The contracts were signed with the companies that, today, are the leaders in new areas of pharmaceutical market and nanotechnology. These companies agreed to work with us, and we will get a new quality of medicinal products,” said Valery Malashko.
Joint Belarusian-Indian pharmaceutical production facilities are scheduled for launch in Belarus in 2017-2018. They will manufacture the drugs for the treatment of cancer, tuberculosis, HIV, and hepatitis; antitumor drugs; and monoclonal antibodies.
“We will start manufacturing these drugs in our country with subsequent deeper localization,” said the minister.
During the Belarusian-Indian business forum held in New Delhi, the parties signed a number of agreements and memorandums. This includes the general agreement on strategic partnership between the Ministry of Health of Belarus and Hetero Labs Limited; a tripartite agreement on major terms of partnership between the Ministry of Health, Glorincor, and Biocon Limited; a tripartite agreement on major terms of partnership between the Ministry of Health, Glorincor, and Cadila Healthcare Limited.